Get started
Author

Gianluca Mauri

Early‐onset colorectal cancer in young individuals
2018 · Gianluca Mauri, Andrea Sartore‐Bianchi, et al. · Molecular Oncology · 636
PDF
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
2022 · Andrea Sartore-Bianchi, Filippo Pietrantonio, et al. · Nature Medicine · 271
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines
2022 · Giulia Martina Cavestro, Alessandro Mannucci, et al. · Clinical Gastroenterology and Hepatology · 148
PDF
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
2022 · Giovanni Crisafulli, Andrea Sartore-Bianchi, et al. · Cancer Discovery · 133
PDF
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis
2017 · Federica Tosi, Elena Magni, et al. · Clinical Colorectal Cancer · 122
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
2019 · Sabrina Arena, Giorgio Corti, et al. · Clinical Cancer Research · 115
PDF
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
2022 · Gianluca Mauri, Pietro Paolo Vitiello, et al. · British Journal of Cancer · 102
PDF
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer
2020 · Federica Tosi, Andrea Sartore-Bianchi, et al. · Clinical Colorectal Cancer · 101
PDF
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies
2018 · Gianluca Mauri, Elio Gregory Pizzutilo, et al. · Cancer Treatment Reviews · 90
Strategies to tackle RAS-mutated metastatic colorectal cancer
2021 · G. Patelli, F. Tosi, et al. · ESMO Open · 86
PDF
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
2020 · G. Mauri, S. Arena, et al. · Annals of Oncology · 86
PDF
Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy
2019 · A.G Russo, A. Andreano, et al. · Cancer Epidemiology · 86
PDF
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities
2020 · Gianluca Mauri, Viviana Gori, et al. · Cancer Treatment Reviews · 78
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
2021 · Gianluca Mauri, Erica Bonazzina, et al. · Cancers · 73
PDF
Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
2021 · Vito Amodio, Gianluca Mauri, et al. · Cancers · 66
PDF
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer
2024 · Davide Ciardiello, Erika Martinelli, et al. · JAMA Network Open · 60
PDF
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
2022 · Erika Durinikova, Nicole M. Reilly, et al. · Clinical Cancer Research · 60
PDF
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer
2017 · Giovanni Germano, Gianluca Mauri, et al. · Clinical Colorectal Cancer · 49
Tumor “age” in early-onset colorectal cancer
2025 · Gianluca Mauri, Giorgio Patelli, et al. · Cell · 42
Early-onset cancers: Biological bases and clinical implications
2024 · Gianluca Mauri, Giorgio Patelli, et al. · Cell Reports Medicine · 42
Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study
2016 · Katia Bencardino, Gianluca Mauri, et al. · Clinical Colorectal Cancer · 42
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
2023 · Giorgio Patelli, Gianluca Mauri, et al. · Clinical Cancer Research · 41
PDF
Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression
2019 · Tommaso Cavalleri, Paolo Bianchi, et al. · Cancer Immunology Research · 41
PDF
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
2024 · Ryan B. Corcoran, Khanh T. Do, et al. · Clinical Cancer Research · 40
PDF
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance
2022 · Vito Amodio, Simona Lamba, et al. · Cancer Cell · 38
PDF
Works count: 199
Citation count: 3,030
H-index: 28
I10-index: 41
Year
Topic
Type